US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US6369116B1
(en)
*
|
1995-06-02 |
2002-04-09 |
Oculex Pharmaceuticals, Inc. |
Composition and method for treating glaucoma
|
ATE226450T1
(de)
*
|
1996-03-05 |
2002-11-15 |
Robert Gurny |
Gepufferte orthoesterpolymere enthaltende arzneimittel
|
FR2748205A1
(fr)
*
|
1996-05-06 |
1997-11-07 |
Debio Rech Pharma Sa |
Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
|
US5942508A
(en)
*
|
1997-02-04 |
1999-08-24 |
Senju Pharmaceutical Co., Ltd. |
Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
|
JP2001513369A
(ja)
*
|
1997-08-11 |
2001-09-04 |
アラーガン・セイルズ・インコーポレイテッド |
改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6890546B2
(en)
*
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US7445792B2
(en)
*
|
2003-03-10 |
2008-11-04 |
Abbott Laboratories |
Medical device having a hydration inhibitor
|
DE19756314C2
(de)
*
|
1997-12-12 |
2000-06-29 |
Roland Bodmeier |
Zubereitung mit verlängerter Verweildauer am Applikationsort
|
ATE315386T1
(de)
*
|
1998-08-06 |
2006-02-15 |
Joerg Dr Dr Schierholz |
Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung
|
EP0985413A1
(de)
*
|
1998-08-06 |
2000-03-15 |
Jörg Michael Dr. Dr. Schierholz |
Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
FR2770134B1
(fr)
*
|
1998-10-28 |
2002-06-07 |
Delab |
Formulations solides ou semi-solides pour administration locale
|
JP2002534139A
(ja)
*
|
1999-01-05 |
2002-10-15 |
マサチューセッツ・アイ・アンド・イア・インファーマリー |
網膜と脈絡膜への経強膜徐放性薬剤標的送達
|
US6113638A
(en)
*
|
1999-02-26 |
2000-09-05 |
Williams; Lytton A. |
Method and apparatus for intervertebral implant anchorage
|
US6331313B1
(en)
*
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US7708711B2
(en)
*
|
2000-04-14 |
2010-05-04 |
Glaukos Corporation |
Ocular implant with therapeutic agents and methods thereof
|
US20010049422A1
(en)
*
|
2000-04-14 |
2001-12-06 |
Phaneuf Matthew D. |
Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6692759B1
(en)
*
|
2000-06-28 |
2004-02-17 |
The Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
US6726918B1
(en)
*
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
EP1637126B1
(de)
*
|
2000-07-05 |
2016-12-14 |
Allergan, Inc. |
Verfahren zur Behandlung von entzündungsbedingten Zuständen der Augen
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
US20030082183A1
(en)
*
|
2000-11-01 |
2003-05-01 |
Wheeler Larry A. |
Methods and compositions for treatment of ocular neovascularization and neural injury
|
WO2002058730A2
(en)
*
|
2000-11-01 |
2002-08-01 |
Allergan, Inc. |
Compositions for treatment of ocular neovascularization
|
BR0115772A
(pt)
|
2000-11-29 |
2004-01-13 |
Oculex Pharm Inc |
Processos para a redução ou para a prevenção da rejeição ao transplante ocular e de implantes intraoculares para uso para o mesmo
|
EP1550471A1
(de)
*
|
2000-11-29 |
2005-07-06 |
Allergan Inc. |
Intraokulare Implantate zur Verhinderung von Transplantatabstossung im Auge
|
KR100446101B1
(ko)
*
|
2000-12-07 |
2004-08-30 |
주식회사 삼양사 |
수난용성 약물의 서방성 제형 조성물
|
US20020082678A1
(en)
*
|
2000-12-22 |
2002-06-27 |
Motasim Sirhan |
Intravascular delivery of mizoribine
|
DE60219607T2
(de)
*
|
2001-01-09 |
2007-12-27 |
Microchips, Inc., Bedford |
Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
|
US7431710B2
(en)
|
2002-04-08 |
2008-10-07 |
Glaukos Corporation |
Ocular implants with anchors and methods thereof
|
US7563255B2
(en)
|
2001-05-03 |
2009-07-21 |
Massachusetts Eye And Ear Infirmary |
Implantable drug delivery device and use thereof
|
US7592016B2
(en)
*
|
2001-06-28 |
2009-09-22 |
Regents Of The University Of California |
Methods for preparing and using implantable substance delivery devices
|
GB0116920D0
(en)
*
|
2001-07-11 |
2001-09-05 |
Sulzer Vascutek Ltd |
Delivery system
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US20030180294A1
(en)
*
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
CN1638734A
(zh)
*
|
2002-02-22 |
2005-07-13 |
参天制药株式会社 |
微粒结膜下给药的药物释放系统
|
CN1638743B
(zh)
*
|
2002-03-11 |
2012-11-07 |
爱尔康公司 |
可植入药物的释放系统
|
US7074426B2
(en)
*
|
2002-03-27 |
2006-07-11 |
Frank Kochinke |
Methods and drug delivery systems for the treatment of orofacial diseases
|
WO2003092665A2
(en)
*
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
CA2484512C
(en)
|
2002-05-17 |
2013-04-16 |
Othera Pharmaceuticals, Inc. |
Treatment of cataracts and other ophthalmic diseases
|
SI1515729T1
(sl)
*
|
2002-06-13 |
2008-08-31 |
Novartis Ag |
Kvaternizirane amonij ciklodekstrinske spojine
|
ES2295647T3
(es)
*
|
2002-07-15 |
2008-04-16 |
Alcon, Inc. |
Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
DE10238310A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Erich Jaeger Gmbh |
Elektrodenanordnung
|
CZ294328B6
(cs)
*
|
2002-08-22 |
2004-11-10 |
Pliva-Lachema A. S. |
Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby
|
EP1536850B1
(de)
*
|
2002-09-06 |
2016-08-10 |
Abbott Laboratories |
Medizinisches gerät mit einem hydratationsinhibitor
|
WO2004028477A2
(en)
*
|
2002-09-29 |
2004-04-08 |
Surmodics, Inc. |
Methods for treatment and/or prevention of retinal disease
|
US20040221855A1
(en)
*
|
2002-10-17 |
2004-11-11 |
Paul Ashton |
Methods for monitoring treatment of disease
|
WO2004034975A2
(en)
*
|
2002-10-17 |
2004-04-29 |
Alkermes Controlled Therapeutics, Inc. |
Sustained release profile modification
|
KR20050085367A
(ko)
*
|
2002-12-04 |
2005-08-29 |
산텐 세이야꾸 가부시키가이샤 |
결막하 데포에 의한 약물 송달 시스템
|
JP2004196787A
(ja)
*
|
2002-12-04 |
2004-07-15 |
Santen Pharmaceut Co Ltd |
結膜下デポによるドラッグデリバリーシステム
|
US20040137059A1
(en)
*
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
EP1594484A2
(de)
*
|
2003-02-17 |
2005-11-16 |
Cipla Ltd. |
Pharmazeutisches pflaster
|
US8012115B2
(en)
|
2003-02-18 |
2011-09-06 |
S.K. Pharmaceuticals, Inc. |
Optic nerve implants
|
US20060167435A1
(en)
*
|
2003-02-18 |
2006-07-27 |
Adamis Anthony P |
Transscleral drug delivery device and related methods
|
BRPI0407693A
(pt)
*
|
2003-02-20 |
2006-03-01 |
Alcon Inc |
uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
|
EP1594511A2
(de)
*
|
2003-02-20 |
2005-11-16 |
Alcon, Inc. |
Glucocorticoid-formulierungen zur behandlung von pathologischer angiogenese im auge
|
US7589107B2
(en)
|
2003-05-19 |
2009-09-15 |
Othera Holding, Inc. |
Amelioration of vitrectomy-induced cataracts
|
US7825134B2
(en)
*
|
2003-05-19 |
2010-11-02 |
Othera Holding, Inc. |
Amelioration of cataracts, macular degeneration and other ophthalmic diseases
|
CA2527121A1
(en)
*
|
2003-06-13 |
2004-12-29 |
Alcon, Inc. |
Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
WO2006071794A2
(en)
|
2004-12-23 |
2006-07-06 |
Ethicon Incorporated |
Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
|
US8491883B2
(en)
*
|
2003-06-27 |
2013-07-23 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
|
US9592258B2
(en)
|
2003-06-27 |
2017-03-14 |
DePuy Synthes Products, Inc. |
Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
|
US8518390B2
(en)
|
2003-06-27 |
2013-08-27 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
|
US9572840B2
(en)
|
2003-06-27 |
2017-02-21 |
DePuy Synthes Products, Inc. |
Regeneration and repair of neural tissue using postpartum-derived cells
|
EP1641913B1
(de)
*
|
2003-06-27 |
2016-01-06 |
DePuy Synthes Products, Inc. |
Aus der nabelschnur abgeleitete postpartum zellen und deren herstellungsmethoden und verwendung
|
US8790637B2
(en)
|
2003-06-27 |
2014-07-29 |
DePuy Synthes Products, LLC |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
US7875272B2
(en)
*
|
2003-06-27 |
2011-01-25 |
Ethicon, Incorporated |
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
|
TWI347847B
(en)
*
|
2003-08-20 |
2011-09-01 |
Santen Pharmaceutical Co Ltd |
Drug delivery system for sub-tenon administration of fine particles
|
WO2005037317A2
(en)
*
|
2003-10-17 |
2005-04-28 |
Cornell Research Foundation, Inc. |
Mast cell-derived renin
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050130906A1
(en)
*
|
2003-11-20 |
2005-06-16 |
Matier William L. |
Amelioration of macular degeneration and other ophthalmic diseases
|
SG149004A1
(en)
|
2003-12-05 |
2009-01-29 |
Bristol Myers Squibb Co |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
US8691258B2
(en)
*
|
2003-12-12 |
2014-04-08 |
Medtronic, Inc. |
Anti-infective medical device
|
WO2005061003A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Medtronic, Inc. |
Anti-infective medical device
|
JP2007518804A
(ja)
|
2004-01-20 |
2007-07-12 |
アラーガン、インコーポレイテッド |
トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
|
US8685435B2
(en)
*
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US7771742B2
(en)
*
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244472A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
BRPI0510485A
(pt)
|
2004-04-30 |
2007-11-13 |
Allergan Inc |
implantes inibidores de tirosina cinase intravìtreos biodegradáveis
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8722097B2
(en)
*
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
AU2011213904B2
(en)
*
|
2004-04-30 |
2014-06-05 |
Allergan, Inc. |
Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
WO2005115375A1
(en)
*
|
2004-05-25 |
2005-12-08 |
Othera Pharmaceuticals, Inc. |
Oculoselective drugs and prodrugs
|
US20060110428A1
(en)
*
|
2004-07-02 |
2006-05-25 |
Eugene Dejuan |
Methods and devices for the treatment of ocular conditions
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
AU2013221985B2
(en)
*
|
2004-07-12 |
2016-09-01 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
EP1781264B1
(de)
|
2004-08-04 |
2013-07-24 |
Evonik Corporation |
Verfahren zur herstellung von abgabevorrichtungen und damit erhaltene vorrichtungen
|
US20160106717A1
(en)
|
2004-09-24 |
2016-04-21 |
Gen Pharma Holdings LLC |
Cai-based systems and methods for the localized treatment of uveitis
|
ES2369554T3
(es)
|
2004-09-24 |
2011-12-01 |
Rfe Pharma Llc |
Carboxi-amido-triazoles para el tratamiento local de enfermedades oculares.
|
US20060068012A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
|
US20060067978A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly(vinyl alcohol) drug delivery devices
|
WO2006039336A2
(en)
|
2004-10-01 |
2006-04-13 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
US8541413B2
(en)
*
|
2004-10-01 |
2013-09-24 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
US9993558B2
(en)
|
2004-10-01 |
2018-06-12 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
US20080038316A1
(en)
*
|
2004-10-01 |
2008-02-14 |
Wong Vernon G |
Conveniently implantable sustained release drug compositions
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
BRPI0518999A2
(pt)
|
2004-12-10 |
2008-12-23 |
Talima Therapeutics Inc |
composiÇÕes e mÉtodos para tratar condiÇÕes da unidade da unha
|
US20060275230A1
(en)
|
2004-12-10 |
2006-12-07 |
Frank Kochinke |
Compositions and methods for treating conditions of the nail unit
|
US20060153815A1
(en)
*
|
2004-12-21 |
2006-07-13 |
Agnieszka Seyda |
Tissue engineering devices for the repair and regeneration of tissue
|
US20060166361A1
(en)
*
|
2004-12-21 |
2006-07-27 |
Agnieszka Seyda |
Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
|
WO2006101548A2
(en)
*
|
2004-12-21 |
2006-09-28 |
Ethicon, Inc. |
Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
|
US20060134174A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bausch & Lomb Incorporated |
Pharmaceutical delivery system and method of use
|
US20060134175A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Stephen Bartels |
Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
|
WO2006071778A2
(en)
|
2004-12-23 |
2006-07-06 |
Ethicon Incorporated |
Treatment of parkinson's disease and related disorders using postpartum derived cells
|
US20060165810A1
(en)
*
|
2004-12-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Controlled release from block co-polymer worm micelles
|
US20060204548A1
(en)
*
|
2005-03-01 |
2006-09-14 |
Allergan, Inc. |
Microimplants for ocular administration
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
US8003124B2
(en)
*
|
2005-04-08 |
2011-08-23 |
Surmodics, Inc. |
Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
|
US7931909B2
(en)
*
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
US20080312283A1
(en)
*
|
2005-05-26 |
2008-12-18 |
Othera Pharmaceuticals, Inc. |
Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
|
BRPI0615962A2
(pt)
|
2005-07-27 |
2011-05-31 |
Univ Florida |
uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional
|
CA2602440A1
(en)
*
|
2005-09-16 |
2007-04-05 |
Allergan, Inc. |
Compositions and methods for the intraocular transport of therapeutic agents
|
SI1937244T1
(sl)
|
2005-09-30 |
2018-12-31 |
Io Therapeutics, Llc |
Zdravljenje raka s specifičnimi RXR agonisti
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
US20070134244A1
(en)
*
|
2005-10-14 |
2007-06-14 |
Alcon, Inc. |
Combination treatment for pathologic ocular angiogenesis
|
MX2007012061A
(es)
|
2005-10-18 |
2007-12-13 |
Allergan Inc |
Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
|
WO2007064752A2
(en)
|
2005-11-29 |
2007-06-07 |
Smithkline Beecham Corporation |
Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
|
WO2007070870A1
(en)
*
|
2005-12-16 |
2007-06-21 |
Ethicon, Inc. |
Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
|
JP5179376B2
(ja)
*
|
2005-12-19 |
2013-04-10 |
エシコン・インコーポレイテッド |
ローラーボトルでの分娩後取り出し細胞の体外増殖
|
US9125906B2
(en)
|
2005-12-28 |
2015-09-08 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
SG170789A1
(en)
*
|
2005-12-28 |
2011-05-30 |
Ethicon Inc |
Treatment of peripheral vascular disease using postpartum-derived cells
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
EP1993584B1
(de)
|
2006-02-02 |
2012-05-30 |
Allergan, Inc. |
CXCR4-Hemmer-Therapie zur Verwendung bei der Behandlung von Augenerkrankungen
|
US20070203190A1
(en)
*
|
2006-02-22 |
2007-08-30 |
Ghanshyam Patil |
Hydroxylamines and derivatives for the inhibition of complement activation
|
US20070232660A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Allergan, Inc. |
Therapeutic and delivery methods of prostaglandin ep4 agonists
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9039761B2
(en)
|
2006-08-04 |
2015-05-26 |
Allergan, Inc. |
Ocular implant delivery assemblies with distal caps
|
US20080089923A1
(en)
*
|
2006-09-29 |
2008-04-17 |
Burkstrand Michael J |
Biodegradable ocular implants and methods for treating ocular conditions
|
US10669383B2
(en)
|
2006-10-31 |
2020-06-02 |
Evonik Corporation |
Spheronized polymer particles
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8586556B2
(en)
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
CA2670990A1
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
US8846073B2
(en)
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
US20090092574A1
(en)
|
2006-12-29 |
2009-04-09 |
Scott Richard W |
Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
|
CN101687786B
(zh)
|
2007-02-22 |
2013-05-22 |
奥特拉控股公司 |
羟胺化合物及其用法
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
US20080292680A1
(en)
*
|
2007-05-14 |
2008-11-27 |
Sustained Nano Systems Llc |
Hypercompressed polymer particles for controlled release ophthalmic medications
|
US8231892B2
(en)
*
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
US20080317805A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Mckay William F |
Locally administrated low doses of corticosteroids
|
WO2009029543A1
(en)
*
|
2007-08-24 |
2009-03-05 |
Aegis Therapeutics, Llc |
Controlled release formulations
|
US20090123508A1
(en)
*
|
2007-10-04 |
2009-05-14 |
Boston Scientific Scimed, Inc. |
Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
|
WO2009046335A1
(en)
*
|
2007-10-05 |
2009-04-09 |
Ethicon, Incorporated |
Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
|
EP2197461B1
(de)
|
2007-10-08 |
2018-02-21 |
Aurinia Pharmaceuticals Inc. |
Ophthalmische zusammensetzungen mit calcineurin-hemmern oder mtor-hemmern
|
US8124601B2
(en)
*
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
EP2222281B1
(de)
|
2007-12-20 |
2018-12-05 |
Evonik Corporation |
Verfahren zur herstellung von mikropartikeln mit geringer restlösemittelmenge
|
US8236538B2
(en)
|
2007-12-20 |
2012-08-07 |
Advanced Technologies And Regenerative Medicine, Llc |
Methods for sterilizing materials containing biologically active agents
|
MX2010008874A
(es)
|
2008-02-14 |
2010-09-22 |
Bristol Myers Squibb Co |
Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
|
US9192571B2
(en)
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
US8524267B2
(en)
*
|
2008-04-18 |
2013-09-03 |
Warsaw Orthopedic, Inc. |
Dexamethasone formulations in a biodegradable material
|
CA2723588A1
(en)
|
2008-05-12 |
2009-11-19 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated uses
|
US10064819B2
(en)
|
2008-05-12 |
2018-09-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9095404B2
(en)
|
2008-05-12 |
2015-08-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
CN102099373A
(zh)
|
2008-05-22 |
2011-06-15 |
百时美施贵宝公司 |
基于纤连蛋白的多价支架结构域蛋白
|
US10517839B2
(en)
*
|
2008-06-09 |
2019-12-31 |
Cornell University |
Mast cell inhibition in diseases of the retina and vitreous
|
US8821870B2
(en)
|
2008-07-18 |
2014-09-02 |
Allergan, Inc. |
Method for treating atrophic age related macular degeneration
|
PT2320911E
(pt)
|
2008-08-01 |
2014-11-11 |
Eye Therapies Llc |
Composições de vasoconstrição e métodos de utilização
|
KR101368736B1
(ko)
*
|
2008-09-25 |
2014-03-05 |
인비보 테라퓨틱스 코포레이션 |
척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출
|
US20100104654A1
(en)
|
2008-10-27 |
2010-04-29 |
Allergan, Inc. |
Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
|
US9095506B2
(en)
*
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
US8034813B2
(en)
*
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
CN102387807A
(zh)
|
2008-12-19 |
2012-03-21 |
先进科技及再生医学有限责任公司 |
肺部疾病和病症的治疗
|
WO2010071863A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Ethicon, Incorporated |
Regeneration and repair of neural tissue following injury
|
US10179900B2
(en)
*
|
2008-12-19 |
2019-01-15 |
DePuy Synthes Products, Inc. |
Conditioned media and methods of making a conditioned media
|
EP2379087B1
(de)
*
|
2008-12-19 |
2014-08-20 |
DePuy Synthes Products, LLC |
Aus nabelschnurgewebe gewonnene zellen zur behandlung von neuropathischen schmerzen und spastizität
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
US20100291182A1
(en)
*
|
2009-01-21 |
2010-11-18 |
Arsenal Medical, Inc. |
Drug-Loaded Fibers
|
US20100204325A1
(en)
*
|
2009-02-11 |
2010-08-12 |
Allergan, Inc. |
Valproic acid drug delivery systems and intraocular therapeutic uses thereof
|
WO2010093945A2
(en)
|
2009-02-13 |
2010-08-19 |
Glaukos Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
US20100239632A1
(en)
*
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
US8722034B2
(en)
*
|
2009-03-26 |
2014-05-13 |
Depuy Synthes Products Llc |
hUTC as therapy for Alzheimer's disease
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
ES2537385T3
(es)
*
|
2009-06-09 |
2015-06-08 |
Aurinia Pharmaceuticals Inc. |
Sistemas de suministro tópico para uso oftálmico
|
IN2012DN00352A
(de)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
WO2010148352A1
(en)
|
2009-06-19 |
2010-12-23 |
Altos Vision Limited |
Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
|
IN2012DN00407A
(de)
*
|
2009-08-05 |
2015-08-21 |
Pieris Ag |
|
US9044580B2
(en)
|
2009-08-24 |
2015-06-02 |
Arsenal Medical, Inc. |
In-situ forming foams with outer layer
|
US10420862B2
(en)
|
2009-08-24 |
2019-09-24 |
Aresenal AAA, LLC. |
In-situ forming foams for treatment of aneurysms
|
US9173817B2
(en)
|
2009-08-24 |
2015-11-03 |
Arsenal Medical, Inc. |
In situ forming hemostatic foam implants
|
US20110202016A1
(en)
*
|
2009-08-24 |
2011-08-18 |
Arsenal Medical, Inc. |
Systems and methods relating to polymer foams
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
WO2011048070A1
(en)
|
2009-10-20 |
2011-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
US20120322882A1
(en)
|
2009-11-09 |
2012-12-20 |
Allergan, Inc. |
Compositions And Methods For Stimulating Hair Growth
|
WO2011075481A1
(en)
|
2009-12-16 |
2011-06-23 |
Allergan, Inc. |
Intracameral devices for sustained delivery
|
CN107184544A
(zh)
|
2010-01-22 |
2017-09-22 |
阿勒根公司 |
前房内持续释放治疗药植入物
|
WO2011106697A1
(en)
|
2010-02-25 |
2011-09-01 |
Schepens Eye Research Institute |
Therapeutic compositions for the treatment of dry eye disease
|
AU2011224445B2
(en)
|
2010-03-08 |
2015-08-27 |
Spectrum Pharmaceuticals, Inc. |
Thioxanthone-based autophagy inhibitor therapies to treat cancer
|
AU2011248108B2
(en)
|
2010-05-04 |
2016-05-26 |
Corium Pharma Solutions, Inc. |
Method and device for transdermal delivery of parathyroid hormone using a microprojection array
|
ES2566934T3
(es)
|
2010-05-10 |
2016-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
|
US9562089B2
(en)
|
2010-05-26 |
2017-02-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
WO2011159824A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
Composition and method for treating overactive bladder
|
CA2803923A1
(en)
|
2010-06-25 |
2011-12-29 |
Ignacio R. Rodriguez |
Methods of treatment using sterculic acid
|
EP2595602B1
(de)
|
2010-07-21 |
2018-05-23 |
Allergan, Inc. |
Retard-sirna für die freisetzung von augenmedikamenten
|
US8697057B2
(en)
|
2010-08-19 |
2014-04-15 |
Allergan, Inc. |
Compositions and soft tissue replacement methods
|
WO2012024072A1
(en)
|
2010-08-19 |
2012-02-23 |
Allergan, Inc. |
Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
|
EP2654715B1
(de)
|
2010-11-24 |
2017-01-25 |
Dose Medical Corporation |
Arzneimittelfreisetzendes augenimplantat
|
EP2661269A1
(de)
|
2011-01-03 |
2013-11-13 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlichen augenkrankheiten
|
US8349005B2
(en)
|
2011-01-03 |
2013-01-08 |
Masatoshi Murata |
Method for burying implant to choroid
|
US8968626B2
(en)
|
2011-01-31 |
2015-03-03 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
US9034240B2
(en)
|
2011-01-31 |
2015-05-19 |
Arsenal Medical, Inc. |
Electrospinning process for fiber manufacture
|
US9194058B2
(en)
|
2011-01-31 |
2015-11-24 |
Arsenal Medical, Inc. |
Electrospinning process for manufacture of multi-layered structures
|
EP2675491A2
(de)
|
2011-02-17 |
2013-12-25 |
Allergan, Inc. |
Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
|
WO2013105997A2
(en)
|
2011-02-23 |
2013-07-18 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
EP2714016A1
(de)
|
2011-06-03 |
2014-04-09 |
Allergan, Inc. |
Gezielte freisetzung von retinoid-verbindungen an die talgdrüsen
|
US10245178B1
(en)
|
2011-06-07 |
2019-04-02 |
Glaukos Corporation |
Anterior chamber drug-eluting ocular implant
|
US9133082B2
(en)
|
2011-06-14 |
2015-09-15 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
WO2012177825A1
(en)
|
2011-06-21 |
2012-12-27 |
Bvw Holding Ag |
Medical device comprising boswellic acid
|
WO2013011511A1
(en)
|
2011-07-18 |
2013-01-24 |
Mor Research Applications Ltd. |
A device for adjusting the intraocular pressure
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US8993831B2
(en)
|
2011-11-01 |
2015-03-31 |
Arsenal Medical, Inc. |
Foam and delivery system for treatment of postpartum hemorrhage
|
CA2862807A1
(en)
|
2011-11-30 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2785178B1
(de)
|
2011-12-01 |
2019-05-01 |
Bikam Pharmaceuticals, Inc. |
Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
|
CA2858161C
(en)
|
2011-12-05 |
2020-03-10 |
Incept, Llc |
Medical organogel processes and compositions
|
CN110151745A
(zh)
|
2011-12-13 |
2019-08-23 |
Io治疗公司 |
使用rxr激动剂的自身免疫紊乱的治疗
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
JP6301263B2
(ja)
|
2011-12-23 |
2018-03-28 |
デピュイ・シンセス・プロダクツ・インコーポレイテッド |
ヒト臍帯組織由来細胞の検出
|
EP2802622A4
(de)
*
|
2012-01-13 |
2015-08-26 |
Univ Missouri |
Niedrigtemperaturplasmabeschichtung für antibiofilmbildung
|
EP2814482A1
(de)
|
2012-02-16 |
2014-12-24 |
Allergan, Inc. |
Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
|
WO2013123275A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123272A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123274A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
EP2900270B1
(de)
|
2012-09-26 |
2019-03-06 |
Tangent Reprofiling Limited |
Kombination von benzo (iso) oxazolepiperidinen mit konjugierter linolsäure
|
CN104812397A
(zh)
*
|
2012-09-27 |
2015-07-29 |
阿勒根公司 |
用于持续释放蛋白质的生物可降解的药物递送系统
|
CA2887893C
(en)
|
2012-10-09 |
2021-07-06 |
Douglas SEARS |
Therapeutic treatment for attention deficit disorder
|
AU2013336683A1
(en)
|
2012-10-24 |
2015-05-14 |
Biocopea Limited |
Drug combinations containing statins for treating cardiovascular diseases
|
ES2879430T3
(es)
|
2012-11-15 |
2021-11-22 |
Apellis Pharmaceuticals Inc |
Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
|
KR102265808B1
(ko)
|
2012-12-21 |
2021-06-16 |
코리움, 인크. |
치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법
|
WO2014108571A2
(en)
|
2013-01-14 |
2014-07-17 |
Biocopea Limited |
Cancer drug and uses
|
NZ710444A
(en)
|
2013-02-11 |
2020-08-28 |
Univ California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
EP2956096A1
(de)
|
2013-02-15 |
2015-12-23 |
Allergan, Inc. |
Implantat mit langzeit-wirkstofffreisetzung
|
RS60026B1
(sr)
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
US9890127B2
(en)
|
2013-03-11 |
2018-02-13 |
The Broad Institute, Inc. |
Compounds and compositions for the treatment of cancer
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
JP6487899B2
(ja)
|
2013-03-12 |
2019-03-20 |
コリウム インターナショナル, インコーポレイテッド |
微小突起アプリケータ
|
EP2967824B1
(de)
|
2013-03-12 |
2020-11-04 |
Carnegie Mellon University |
Beschichtete vasookklusive vorrichtung zur behandlung von aneurysmen
|
BR112015022025A8
(pt)
|
2013-03-14 |
2019-12-10 |
Hallux Inc |
composição e uso de um agente ativo
|
US10517759B2
(en)
|
2013-03-15 |
2019-12-31 |
Glaukos Corporation |
Glaucoma stent and methods thereof for glaucoma treatment
|
WO2014151769A1
(en)
|
2013-03-15 |
2014-09-25 |
Allergan, Inc. |
Compositions including encapsulated isotretinoin and methods for use thereof
|
MX2015012933A
(es)
|
2013-03-15 |
2016-09-19 |
Corium Int Inc |
Micrordenamiento para suministro de agente terapeutico y metodos de uso.
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
EP2994758B1
(de)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarker für altersbedingte makuladegeneration (amd)
|
CA2922095C
(en)
|
2013-08-21 |
2021-12-28 |
Senseonics, Incorporated |
Drug elution for in vivo protection of bio-sensing analytes
|
JP6543431B2
(ja)
*
|
2013-10-10 |
2019-07-10 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation |
眼内薬物送達デバイスおよび付随する方法
|
WO2015116709A1
(en)
|
2014-01-28 |
2015-08-06 |
Allergan, Inc. |
Topical retinoid formulations and methods of use
|
CA2939219C
(en)
|
2014-02-11 |
2023-02-28 |
Mitokinin Llc |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
EP3132804B1
(de)
|
2014-04-17 |
2021-05-05 |
Seed Co., Ltd. |
Medizinische vorrichtung mit anionischem arzneimittel
|
EP3148491B1
(de)
|
2014-05-29 |
2020-07-01 |
Glaukos Corporation |
Implantate mit kontrollierter arzneimittelfreisetzung und herstellungsverfahren davon
|
WO2016005599A1
(en)
|
2014-07-10 |
2016-01-14 |
Biocopea Limited |
Compositions, methods and uses for treating gender-biased immune disorders
|
EP3188714A1
(de)
|
2014-09-04 |
2017-07-12 |
Corium International, Inc. |
Mikrostrukturanordnung, verfahren zur herstellung und verfahren zur verwendung
|
EP3265165B1
(de)
|
2015-03-06 |
2020-08-19 |
Aerie Pharmaceuticals, Inc. |
Implantatapplikatoren
|
US10857093B2
(en)
|
2015-06-29 |
2020-12-08 |
Corium, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
CA2993340C
(en)
|
2015-07-23 |
2024-04-30 |
Aerie Pharmaceuticals, Inc. |
Intravitreal drug delivery systems for the treatment of ocular conditions
|
EP3328886B1
(de)
|
2015-07-29 |
2020-09-16 |
Allergan, Inc. |
Schwere-ketten-antikörper gegen ang-2
|
JP2018523673A
(ja)
|
2015-08-14 |
2018-08-23 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
Pdgfに対する重鎖のみ抗体
|
US10246436B2
(en)
|
2015-09-02 |
2019-04-02 |
Trevena, Inc. |
6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
|
WO2017040853A1
(en)
|
2015-09-02 |
2017-03-09 |
Glaukos Corporation |
Drug delivery implants with bi-directional delivery capacity
|
US11564833B2
(en)
|
2015-09-25 |
2023-01-31 |
Glaukos Corporation |
Punctal implants with controlled drug delivery features and methods of using same
|
ES2974107T3
(es)
|
2015-10-07 |
2024-06-25 |
Apellis Pharmaceuticals Inc |
Regímenes de dosificación
|
US12048761B2
(en)
*
|
2015-10-13 |
2024-07-30 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
EP4088719A1
(de)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
|
WO2017064121A1
(en)
|
2015-10-13 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
|
AU2016344018B2
(en)
|
2015-10-31 |
2019-02-28 |
Io Therapeutics, Inc. |
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
|
PT109154B
(pt)
*
|
2016-02-12 |
2019-11-05 |
Univ De Coimbra |
Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
|
US10835507B2
(en)
|
2016-03-10 |
2020-11-17 |
Io Therapeutics, Inc. |
Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
|
CN115227826A
(zh)
|
2016-03-10 |
2022-10-25 |
Io治疗公司 |
Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
WO2017184436A1
(en)
*
|
2016-04-17 |
2017-10-26 |
Children's Medical Center Corporation |
Systems and methods for steroidal gels
|
CN115120405A
(zh)
|
2016-04-20 |
2022-09-30 |
多斯医学公司 |
生物可吸收眼部药物的递送装置
|
CN109414460A
(zh)
|
2016-07-05 |
2019-03-01 |
詹森生物科技公司 |
使用祖细胞治疗视网膜血管病
|
EP3484463B1
(de)
|
2016-08-19 |
2020-02-12 |
The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer |
Selektive östrogenrezeptormodulatoren (serm) zur verleihung von schutz gegen photorezeptordegeneration
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
CN110520129A
(zh)
|
2017-02-17 |
2019-11-29 |
特维娜有限公司 |
含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
|
JP7185633B2
(ja)
|
2017-02-17 |
2022-12-07 |
トレベナ・インコーポレイテッド |
7員アザ複素環を含有するデルタ-オピオイド受容体調節化合物、その使用方法及び製造方法
|
JP2020516607A
(ja)
|
2017-04-07 |
2020-06-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. |
投与レジメンならびに関連組成物および方法
|
CA3060956A1
(en)
|
2017-05-05 |
2018-11-08 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Ocular applications of matrix bound vesicles (mbvs)
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
|
WO2019033119A1
(en)
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|
WO2019060600A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
CA3195810A1
(en)
|
2017-10-16 |
2022-04-21 |
Michael Bruce Horowitz |
Clot removal methods and devices with multiple independently controllable elements
|
US10172634B1
(en)
|
2017-10-16 |
2019-01-08 |
Michael Bruce Horowitz |
Catheter based retrieval device with proximal body having axial freedom of movement
|
US20220104839A1
(en)
|
2017-10-16 |
2022-04-07 |
Retriever Medical, Inc. |
Clot Removal Methods and Devices with Multiple Independently Controllable Elements
|
US11739326B2
(en)
|
2017-11-14 |
2023-08-29 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
JP7356994B2
(ja)
|
2018-03-02 |
2023-10-05 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
網膜炎症および神経変性を処置するためのil-34の使用
|
MX2020011535A
(es)
*
|
2018-05-01 |
2020-11-24 |
Chibi Inc |
Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
|
WO2020092897A1
(en)
|
2018-11-02 |
2020-05-07 |
Senseonics, Incorporated |
Drug eluting matrix on analyte indicator
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
US11471426B2
(en)
|
2019-10-16 |
2022-10-18 |
American River Nutrition, Llc |
Compositions comprising quinone and/or quinol and methods of preparations and use thereof
|
EP4072521A1
(de)
*
|
2019-12-10 |
2022-10-19 |
Alcon Inc. |
Auflösbare polymere augeneinsätze mit einem biologisch abbaubaren polymer
|
WO2021146625A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
US20230226138A1
(en)
|
2020-06-01 |
2023-07-20 |
Black Cat Bio Limited |
Compositions and methods for treating infections and netopathy
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|
AU2022407454A1
(en)
|
2021-12-07 |
2024-06-06 |
Board Of Regents, The University Of Texas System |
Use of an rxr agonist in treating drug resistant her2+ cancers
|
WO2023108012A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist and taxanes in treating her2+ cancers
|
US11779553B1
(en)
*
|
2022-11-28 |
2023-10-10 |
Atif B. D. Collins |
Methods and devices for treatment of eyelid ptosis
|